AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients. METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not. RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.
AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabeticpatients. METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not. RESULTS: A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.
Authors: Karin D Hove; Kristine Færch; Thóra B Bödvarsdóttir; Allan E Karlsen; Jacob S Petersen; Allan Vaag Journal: Diabetes Res Clin Pract Date: 2010-12 Impact factor: 5.602
Authors: Wilma L Suarez-Pinzon; Jonathan R T Lakey; Stephen J Brand; Alex Rabinovitch Journal: J Clin Endocrinol Metab Date: 2005-03-15 Impact factor: 5.958
Authors: F Inci; M Atmaca; M Ozturk; S Yildiz; R Koceroglu; R Sekeroglu; S H Ipekci; L Kebapcilar Journal: J Endocrinol Invest Date: 2014-01-09 Impact factor: 4.256
Authors: K D Hove; C Brøns; K Færch; S S Lund; J S Petersen; A E Karlsen; P Rossing; J F Rehfeld; A Vaag Journal: Diabetologia Date: 2012-09-26 Impact factor: 10.122
Authors: Olga Kruszelnicka; Marcin Kuźma; Iwona Z Pena; Ian B Perera; Bernadeta Chyrchel; Ewa Wieczorek-Surdacka; Andrzej Surdacki Journal: Int J Med Sci Date: 2017-09-02 Impact factor: 3.738